GMAB:OMXCOPGenmab A/S analysis
Data as of Sep 26, 2026 - not real-time
- Latest price
- $35.32
- Risk: medium
- 5/10Medium risk
Summary
Genmab A/S is priced at $35.32 and its moving averages line up in bullish order, the shorter sitting above the longer. The last 30 days have gained 12.7%. RSI sits at 65.7, which reads as approaching overbought, and MACD momentum is bullish. Watch $32.21 as support and $35.66 as the nearer resistance level.
Multiples put this in fair territory: 28.0 times earnings against the sector's 30.5. Consensus targets land 10.8% above where the shares trade now. Revenue is growing at 24.9% on a 19.1% profit margin.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 29.7%, a beta of 0.77 and a maximum drawdown of 32.5%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on buy, with conviction of 6/10.
Multiples put this in fair territory: 28.0 times earnings against the sector's 30.5. Consensus targets land 10.8% above where the shares trade now. Revenue is growing at 24.9% on a 19.1% profit margin.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 29.7%, a beta of 0.77 and a maximum drawdown of 32.5%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on buy, with conviction of 6/10.
Top market events
- Genmab A/S NASDAQ:GMAB boosted its full-year 2026 revenue guidance to a range of $4.
- Genmab stock trades in the mid-$30s on Nasdaq as updated 2026 revenue guidance leans more heavily on
- Genmab stock trades in the mid-$30s range as the Danish biotech lifts its 2026 revenue outlook on gr
Market outlook
Short term
< 1 yearPositive
Model confidence7/107 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 29.53
- MACD momentum is positive
Medium term
1–3 yearsPositive
Model confidence7/107 out of 10
Key factors
- Short-term moving averages stacked above long-term ones
- P/E of 28.0 versus sector average of 30.5
- Trading above the 200-day average of 29.53
Long term
> 3 yearsPositive
Model confidence6/106 out of 10
Key factors
- P/E of 28.0 versus sector average of 30.5
- Analyst targets imply +10.8% versus the current price
- Profit margin of 19.1% is healthy
Key metrics
Financial health
Revenue Growth24.90%
Profit Margin19.07%
P/E Ratio28.0
ROE14.00%
ROA8.79%
Debt/Equity88.52
P/B Ratio3.5
Op. Cash Flow$891.0M
Free Cash Flow$870.6M
Industry P/E30.5
Technical analysis
TrendBullish
RSI65.7
Support$32.21
Resistance$35.66
MA 20$33.92
MA 50$32.01
MA 200$29.53
MACDBullish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Fair Value$39.73
Target Price$39.14
Upside/Downside10.81%
GradeFair
TypeGrowth
Risk assessment
Beta0.77
Volatility29.70%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.